Free lookups: 1/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
1 of 3 free lookups remaining Upgrade
New search Medicine profile Fluticasone propionate nasal spray

Clinical medicine profile

Fluticasone propionate nasal spray

Corticosteroid

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
ORAL / IV / IM / INHALED / TOPICAL / NASAL / OPHTHALMIC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Systemic fungal infections (untreated) for systemic steroids.
  • Live vaccines with significant immunosuppression.
  • Hypersensitivity.
  • Topical: untreated skin infection at site (relative).

Precautions

  • Shortest course, lowest dose.
  • Taper after prolonged systemic use.
  • Infection risk, hyperglycaemia, BP rise, mood changes, osteoporosis, avascular necrosis, glaucoma/cataract.
  • Adrenal insufficiency on withdrawal.
  • Stress-dose cover if indicated.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Children 4-11yrs: inhale into each nostril OD, increased to BD [max. 4 sprays daily]. Adults and children over 12yrs: inhale two sprays OD to a max. of 8 sprays daily.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Fluid retention/hypertension — care in renal disease.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Prednisone needs hepatic activation to prednisolone.

03 Clinical use

Use, effects & interactions

Indications

  • Therapeutic use is agent- and indication-specific within the class (Corticosteroid).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.

Adverse effects

  • Insomnia, increased appetite, mood lability, dyspepsia, hyperglycaemia.
  • Chronic: cushingoid features, myopathy, osteoporosis, HPA suppression.
  • Topical: skin atrophy, striae.
  • Inhaled: thrush, dysphonia.
  • State indication and planned duration on every prescription.
  • Bone protection if prolonged.
  • Screen for strongyloides risk before prolonged high-dose in endemic exposure.
  • ICS: spacer + rinse mouth.
04 Pharmacology

Mechanism & disposition

Corticosteroids bind intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory cytokines, inhibit phospholipase A2 via lipocortins, reduce leukocyte migration and stabilise membranes — potent anti-inflammatory and immunosuppressive effects.

Corticosteroids bind intracellular glucoco…Mineralocorticoid activity varies by agent…
Read complete mechanism

Corticosteroids bind intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory cytokines, inhibit phospholipase A2 via lipocortins, reduce leukocyte migration and stabilise membranes — potent anti-inflammatory and immunosuppressive effects. Mineralocorticoid activity varies by agent.

Onset

Hours–days

Duration

Agent and route dependent

Route

ORAL / IV / IM / INHALED / TOPICAL / NASAL / OPHTHALMIC

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Used when maternal benefit clear; prefer agents with better obstetric data (e.g. prednisolone). Document risk–benefit.

Lactation

Low-dose systemic often compatible; time feeds if high dose — agent-specific.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Professional class pharmacology (Corticosteroid)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.